<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="285">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884191</url>
  </required_header>
  <id_info>
    <org_study_id>PAC203</org_study_id>
    <nct_id>NCT04884191</nct_id>
  </id_info>
  <brief_title>Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib</brief_title>
  <official_title>Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CTI BioPharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was an open-label, randomized, dose-finding study in patients with primary or secondary&#xD;
      MF (Dynamic International Prognostic Scoring System [DIPSS] risk score of Intermediate-1 to&#xD;
      High-Risk) who were previously treated with ruxolitinib. The study was designed to support a&#xD;
      pacritinib dosage selection decision with evaluation of 3 dosages.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Actual">September 4, 2019</completion_date>
  <primary_completion_date type="Actual">September 4, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spleen Volume Reduction Response (≥ 35%)</measure>
    <time_frame>From Baseline to Weeks 12 and 24</time_frame>
    <description>Number of patients achieving a ≥ 35% spleen volume reduction (SVR) as measured by magnetic resonance imaging (MRI, preferred) or computed tomography (CT) scans</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spleen Volume</measure>
    <time_frame>From Baseline to Weeks 12 and 24</time_frame>
    <description>Percent change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Symptom Score Analysis</measure>
    <time_frame>From Baseline to Weeks 12 and 24</time_frame>
    <description>Proportion of patients with ≥ 50% reduction in Total Symptom Score from baseline as assessed by the validated PRO instrument MPN-SAF TSS 2.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Global Impression Assessment</measure>
    <time_frame>From Baseline to Weeks 12 and 24</time_frame>
    <description>Number of patients with improvement in PGIA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spleen Length Reduction</measure>
    <time_frame>From Baseline to Weeks 24</time_frame>
    <description>Rate of reduction in spleen length from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of RBC's or platelet Transfusions</measure>
    <time_frame>At week 24</time_frame>
    <description>Number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eastern Cooperative Oncology Group Performance Status</measure>
    <time_frame>At weeks 4, 12, 24, and 30 days post End-of-Treatment visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: number of Adverse Events</measure>
    <time_frame>Randomization through 30 days post End-of-Treatment visit</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Primary Myelofibrosis</condition>
  <condition>Post-Polycythemia Vera Myelofibrosis</condition>
  <condition>Post- Essential Thrombocythemia Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Pacritinib 100 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pacritinib 100 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pacritinib 200 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pacritinib</intervention_name>
    <description>Pacritinib</description>
    <arm_group_label>Pacritinib 100 mg BID</arm_group_label>
    <arm_group_label>Pacritinib 100 mg QD</arm_group_label>
    <arm_group_label>Pacritinib 200 mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. PMF, PPV-MF, or PET-MF (as defined by Tefferi and Vardiman 2008)&#xD;
&#xD;
          2. DIPSS Intermediate-1, Intermediate -2, or High-risk (Passamonti et al 2010)&#xD;
&#xD;
          3. Prior ruxolitinib treatment with failure to benefit or intolerance as defined by at&#xD;
             least one of the following:&#xD;
&#xD;
               1. Treatment for ≥3 months with inadequate efficacy response defined as &lt;10% SVR by&#xD;
                  MRI or &lt;30% decrease from baseline in spleen length by physical examination or&#xD;
                  regrowth to these parameters following an initial response; and/or&#xD;
&#xD;
               2. Treatment for ≥28 days complicated by either&#xD;
&#xD;
             i. Development of a red blood cell (RBC) transfusion requirement (at least 2&#xD;
             units/month for 2 months) ii. National Cancer Institute (NCI) CTCAE grade ≥3 AEs of&#xD;
             thrombocytopenia, anemia, hematoma, and/or hemorrhage while being treated with a&#xD;
             dosage of &lt;20 mg BID&#xD;
&#xD;
          4. Palpable splenomegaly ≥5 cm below the lower costal margin (LCM) in the midclavicular&#xD;
             line as assessed by physical examination&#xD;
&#xD;
          5. TSS of ≥10 on the MPN-SAF TSS 2.0 or patients with a single symptom score of ≥5 or 2&#xD;
             symptoms of ≥3, including only the symptoms of left upper quadrant pain, bone pain,&#xD;
             itching, or night sweats&#xD;
&#xD;
          6. Age ≥18 years old&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2&#xD;
&#xD;
          8. Peripheral blast count of &lt;10% throughout the Screening period&#xD;
&#xD;
          9. Absolute neutrophil count of &gt;500/μL&#xD;
&#xD;
         10. Adequate liver and renal function, defined by liver transaminases (aspartate&#xD;
             aminotransferase [AST]/serum glutamic-oxaloacetic transaminase [SGOT] and alanine&#xD;
             aminotransferase [ALT]/serum glutamic-pyruvic transaminase [SGPT]), ≤3 × the upper&#xD;
             limit of normal (ULN) (AST/ALT ≤5 × ULN, if transaminase elevation is related to MF),&#xD;
             direct bilirubin ≤4× ULN, and creatinine ≤2.5 mg/dL&#xD;
&#xD;
         11. Adequate coagulation function, defined by prothrombin time (PT)/international&#xD;
             normalized ratio (INR), partial thromboplastin time (PTT), or thrombin time (TT) of&#xD;
             ≤1.5 × ULN&#xD;
&#xD;
         12. Left ventricular cardiac ejection fraction of ≥45% by echocardiogram or multigated&#xD;
             acquisition (MUGA) scan&#xD;
&#xD;
         13. If fertile, willing to use effective birth control methods during the study&#xD;
&#xD;
         14. Willing to undergo and able to tolerate frequent MRI or CT scan assessments during the&#xD;
             study&#xD;
&#xD;
         15. Able to understand and willing to complete symptom assessments using a PRO instrument&#xD;
&#xD;
         16. Provision of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life expectancy &lt;6 months&#xD;
&#xD;
          2. Completed allogeneic stem cell transplant (allo-SCT) or are eligible for and willing&#xD;
             to complete allo-SCT&#xD;
&#xD;
          3. History of splenectomy or planning to undergo splenectomy&#xD;
&#xD;
          4. Splenic irradiation within the last 6 months&#xD;
&#xD;
          5. Previously treated with pacritinib&#xD;
&#xD;
          6. Patients receiving high-dose ruxolitinib (more than 10 mg BID or 20 mg QD) who cannot&#xD;
             tolerate tapering down ruxolitinib to 10 mg BID or less prior to the first dose of&#xD;
             pacritinib&#xD;
&#xD;
          7. Treatment with anticoagulation or antiplatelet agents, except for aspirin dosages of&#xD;
             ≤100 mg per day, within the last 2 weeks&#xD;
&#xD;
          8. Treatment with a strong CYP3A4 inhibitor or a strong cytochrome P450 inducer within&#xD;
             the last 2 weeks&#xD;
&#xD;
          9. Treatment with medications that can prolong the QTc interval within the last 2 weeks&#xD;
&#xD;
         10. Treatment with an experimental therapy within the last 28 days&#xD;
&#xD;
         11. Significant recent bleeding history defined as NCI CTCAE grade ≥2 within the last 3&#xD;
             months, unless precipitated by an inciting event (eg, surgery, trauma, or injury)&#xD;
&#xD;
         12. Any history of CTCAE grade ≥2 non-dysrhythmia cardiac conditions within the last 6&#xD;
             months. Patients with asymptomatic grade 2 non-dysrhythmia cardiac conditions may be&#xD;
             considered for inclusion, with the approval of the medical monitor, if stable and&#xD;
             unlikely to affect patient safety.&#xD;
&#xD;
         13. New York Heart Association Class II, III, or IV congestive heart failure&#xD;
&#xD;
         14. Any history of CTCAE grade ≥2 cardiac dysrhythmias within the last 6 months. Patients&#xD;
             with non-QTc CTCAE grade 2 cardiac dysrhythmias may be considered for inclusion, with&#xD;
             the approval of the medical monitor, if the dysrhythmias are stable, asymptomatic, and&#xD;
             unlikely to affect patient safety.&#xD;
&#xD;
         15. QTc prolongation &gt;450 ms based on the mean of triplicate ECGs or other factors that&#xD;
             increase the risk for QT interval prolongation (eg, heart failure, hypokalemia&#xD;
             [defined as serum potassium &lt;3.0 mEq/L that is persistent and refractory to&#xD;
             correction], family history of long QT interval syndrome, or concomitant use of&#xD;
             medications that may prolong QT interval)&#xD;
&#xD;
         16. Any active gastrointestinal or metabolic condition that could interfere with&#xD;
             absorption of oral medication&#xD;
&#xD;
         17. Active or uncontrolled inflammatory or chronic functional bowel disorder such as&#xD;
             Crohn's Disease, inflammatory bowel disease, chronic diarrhea, or constipation&#xD;
&#xD;
         18. Other malignancy within the last 3 years, other than curatively treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated&#xD;
             nonmetastatic prostate cancer with negative prostate-specific antigen, in situ breast&#xD;
             carcinoma after complete surgical resection, or superficial transitional cell bladder&#xD;
             carcinoma&#xD;
&#xD;
         19. Uncontrolled intercurrent illness, including, but not limited to, ongoing active&#xD;
             infection or psychiatric illness or social situation that, in the judgment of the&#xD;
             treating physician, would limit compliance with study requirements&#xD;
&#xD;
         20. Known seropositivity for human immunodeficiency virus&#xD;
&#xD;
         21. Known active hepatitis A, B, or C virus infection&#xD;
&#xD;
         22. Women who are pregnant or lactating&#xD;
&#xD;
         23. Concurrent enrollment in another interventional trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Faculty Associates, Inc.</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Agnes Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio School of Medicine</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes - Hopital Universitaire Caremeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Toulouse- Hôpital Purpan</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE AOK I. sx. Belgyogyaszati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Központ</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mór Oktató Kórház</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura Dei Tumori</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Monza - Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Center</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust - The Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 2ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust - Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust - Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>August 23, 2021</submitted>
    <returned>September 16, 2021</returned>
    <submitted>September 23, 2021</submitted>
    <returned>October 20, 2021</returned>
    <submitted>October 21, 2021</submitted>
    <returned>November 18, 2021</returned>
    <submitted>November 18, 2021</submitted>
    <returned>December 15, 2021</returned>
    <submitted>December 17, 2021</submitted>
    <returned>January 14, 2022</returned>
    <submitted>January 14, 2022</submitted>
    <submission_canceled>February 3, 2022</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

